Source comparison
Does MK-677 Help Sleep Quality Research?: Safety, Side Effects & Duration Comparison
REM sleep increase (vs baseline) +50% (clinical trial data) No significant change (suppresses pulsatility) +8–12% (modest effect) MK-677 demonstrates the largest polysomnography-confirmed REM improvement of any tested sleep intervention Stage 4 deep sleep incr
This comparison does not assign a generated winner or score.
- REM sleep increase (vs baseline)
- +50% (clinical trial data)
- No significant change (suppresses pulsatility)
- +8–12% (modest effect)
- MK-677 demonstrates the largest polysomnography-confirmed REM improvement of any tested sleep intervention
- Stage 4 deep sleep increase
- +20% (delta wave duration)
- Variable—may decrease in some users
- +15% in elderly only
- MK-677's effect on slow-wave sleep is dose-dependent and reproducible across age groups
- Time to measurable effect
- 7–14 days
- 2–4 weeks
- 1–3 nights
- MK-677 requires consistent nightly use for 2 weeks minimum before sleep architecture changes become detectable
- Common side effects
- Increased appetite (70% of users), transient water retention, fasting glucose elevation (+5–10 mg/dL)
- Joint pain, insulin resistance, gynecomastia risk
- Daytime drowsiness, headache
- MK-677's appetite increase is mediated by ghrelin receptor activation and appears within 48 hours—unrelated to sleep mechanism
- Regulatory status
- Research chemical—not FDA-approved for human use
- Prescription-only (growth hormone deficiency)
- OTC supplement
- MK-677 is legally sold as a research compound but is not approved for therapeutic use in humans
- Typical research duration
- 2–8 weeks (trial data)
- Months to years (clinical use)
- Indefinite
- Long-term MK-677 sleep data beyond 8 weeks is sparse—most trials end before desensitisation can be assessed